

R H I N O M E D

SURESCREEN FIRST ORDER FOR RHINOSWAB JUNIORS

- SureScreen Australia has ordered 250,000 Rhinoswab Juniors under the 10 million swabs over 2 years supply deal
- Rhinoswab Junior to be included in Australia's first rapid antigen test kit for SARS CoV-2 designed for children aged 4+

17 August 2022: Melbourne, Australia.

Rhinomed Limited (ASX:RNO OTCQB:RHNMF), a leader in wearable nasal and respiratory technology, has received the first purchase order for 250,000 Rhinoswab Juniors. This is the first purchase order as part of the 10 million swabs over 2 years supply deal previously announced (18 July 2022).

The Rhinoswab Juniors will be included in the new *SureScreen SARS-CoV-2 Antigen Rapid test cassette Gold* for children. This rapid antigen test kit is registered on the ARTG and is the first designed specifically for children aged 4-12 on the Australian market.

Globally, children remain a critically vulnerable population group for SARS-Cov-2, yet the traumatic nature of swabbing with traditional nasal swabs leads to reluctance and inconsistent testing. A study by the Royal Children's Hospital Melbourne had previously shown that between 30-80% of parents are reluctant to bring their children forward for testing due to the trauma associated with testing. A more recent clinical trial by the Murdoch Children's Research Institute and Royal Children's Hospital Melbourne showed that the Rhinoswab Junior has not only clinical equivalence to the highly invasive combined nose and throat swabs but was preferred by eight out of 10 children.*



R H I N O M E D

The company expects more orders to follow as SureScreen Australia begins rolling out the new test kit in the Australian, New Zealand, Singapore and South Pacific markets.

Company	Investor and Media Relations
Michael Johnson, CEO & Director +61 (0) 3 8416 0900 mjohnson@rhinomed.global Follow us on Twitter @rhinomedceo	Rudi Michelson Monsoon Communications +61(0) 411 402 737 rudim@monsoon.com.au

About Rhinomed Limited (ASX: RNO, OTCQB:RHNMF)

Rhinomed Limited is a Melbourne, Australia based ASX listed nasal and airway technology company that has developed an innovative nasal technology platform that can improve air flow and provide both drug delivery and diagnostic capabilities.

- Tosif S, Lee L, Nguyen J, Overmars I, Selman C, Grobler A, McMinn A, Waller G, McNab S, Jarvis T, Steer A, Babl F, Daley A, Crawford N, *A novel anterior nasal swab to detect respiratory viruses*. In: Communicable Diseases & Immunisation Conference 2022; 20-22nd June, Sydney